Validation of the postnatal growth and retinopathy of prematurity criteria in Taiwanese: A prospective cohort study.
Growth and Retinopathy of Prematurity criteria reduced unnecessary eye exams in premature infants without retinopathy of prematurity.
Validation of the postnatal growth and retinopathy of prematurity criteria in Taiwanese: A prospective cohort study.
While the Postnatal Growth and Retinopathy of Prematurity (Growth and Retinopathy of Prematurity) screening criteria have undergone retrospective validation across various populations, prospective validation is essential before these criteria can be recommended for clinical use and wider adoption.
This prospective study included 114 premature infants who were admitted to the neonatal intensive care unit between December 2019 and August 2024.
less unnecessary eye exams for babies without disease
Using the Growth and Retinopathy of Prematurity criteria, 89 of 89 (specificity 100%) infants without ROP were accurately excluded, while a sensitivity of 88.0%, a positive predictive value (positive predictive value) of 100.0% and a negative predictive value (negative predictive value) of 96.7% for any ROP were identified.
This criterion exhibited a sensitivity of 87.5%, a specificity of 100.0%, a positive predictive value of 100.0% and a negative predictive value of 100.0% for identifying type 1 ROP; a sensitivity of 100.0%, a specificity of 100.0%, a positive predictive value of 100% and a negative predictive value of 98.9% for identifying type 2 ROP; and a sensitivity of 0%, a specificity of 100.0%, a positive predictive value of 0% and a negative predictive value of 97.8% for identifying A-ROP.
This prospective study demonstrated that Growth and Retinopathy of Prematurity criteria are generalizable and may reduce lower-risk infants (who did not develop treatment-requiring ROP during follow-up) receiving examination, exhibiting higher sensitivity, specificity, positive predictive value and negative predictive value for ROP detection than currently recommended guideline.